quadruplet induction therapy in newly diagnosed high-risk myeloma
Published 4 months ago • 108 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:41
quadruplet induction therapy as a new standard of care in multiple myeloma
-
5:27
uvea-ixa: exploring the use of ixazomib-based therapy in r/r myeloma outside of clinical trials
-
3:40
the mutagenic impact of radiotherapy & chemotherapy in multiple myeloma and lymphoma
-
0:39
the changing landscape of induction therapy for newly diagnosed multiple myeloma
-
1:47
abnormal serum immunofixation patterns following bcma car-t in multiple myeloma
-
1:15
the current status and future of car-t therapy in r/r myeloma
-
1:18
standardizing mrd techniques after fda approval as a surrogate endpoint in myeloma trials
-
1:34
determinants of response to quadruplet therapy in multiple myeloma: genomic determinants & nk cells
-
2:17
extended follow-up of the master trial
-
2:16
quadruplet therapy with and without autohsct in ndmm
-
3:48
trials of interest in newly diagnosed myeloma presented at ims 2024
-
2:06
ims session highlights: high-risk myeloma
-
1:57
using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
-
1:40
utilizing ai for individualized treatment-adjusted risk stratification in newly diagnosed myeloma
-
3:56
real-world analysis of treatment patterns and outcomes in newly diagnosed myeloma
-
2:17
advancements in quadruplet regimens for the treatment of multiple myeloma
-
2:11
current treatment landscape of newly diagnosed multiple myeloma
-
2:46
managing patients with high-risk myeloma